Table 6. Predictive scenarios for the rabies field over the next decade.

Likely events	Supportive citations
Broadened surveillance for new lyssavirus species among bats and other mammals	170
Prediction and documentation of associated mammalian species reservoir status for unresolved lyssaviruses (e.g. Mokola, Shimoni, etc.)	171
Better appreciation of bat reservoirs in suggestive “rabies-free” areas, such as islands	172
Refinement of linear flow and related assays for improved “point of care” use in the rapid diagnosis of lyssaviruses	173
Movement beyond pilot projects towards actual national canine rabies elimination in Asia	120
Demonstration of regional elimination of human rabies mediated via dogs in Africa	174
Clinical trials of new biologics to reduce or replace the use of rabies immunoglobulins	175
Expansion of human monoclonal antibodies breadth against divergent lyssaviruses	176
Licensing of purified, serum-free rabies vaccines, with updated label claims for intradermal use	177
Considerations on the use of oral rabies vaccines for other species, such as bats	178
Use of a single vaccine dose for pre-exposure vaccination in remote communities at risk	179
Abandonment of animal testing in the determination of vaccine potency	180,198
Evidence in support of anti-viral drug use based upon insight to viral targets	30
Programmatic use of oral vaccination of dogs for control among free-ranging animals	181
Elimination of canine rabies in Latin America and better “south-south” engagements for repetition of best practices beyond technology	182
“In situ genomic surveillance” expansion within lesser developed countries	183
Protection of “free regions” by expansive elimination of canine rabies in enzootic areas	184
Utilization of Gavi support for human rabies vaccination into national health programs	185